Comparing Tirzepatide and Retatrutide: Clinical Evidence Insights
This article reviews tirzepatide vs retatrutide clinical evidence focusing on their mechanisms and outcomes. Tirzepatide is FDA-approved for diabetes and weight loss, while retatrutide remains investigational. Understanding this clinical evidence helps…
GLP-1 Drugs Compared: Clinical Evidence & Outcomes
GLP-1 receptor agonist family medicine plays a crucial role in managing type 2 diabetes and obesity. This article compares clinical evidence for semaglutide, tirzepatide, and other agents. Understanding these drugs helps clinicians optimize patient…
GLP-1 Receptor Agonists: Safety and Clinical Evidence
This article provides a detailed GLP-1 receptor agonists safety profile review based on current clinical evidence. It covers common side effects, serious risks, and patient counseling essentials. Understanding this safety profile helps optimize treatment…
Policy Watch: 20 Regulatory Updates — June 19, 2026
This update covers the DEA Schedule I synthetic cannabinoids control update as of June 19, 2026. It details regulatory actions impacting synthetic cannabinoids and related substances. The report informs clinical practice and legal considerations.
Schedules of Controlled Substances: Rescheduling FDA-Approved Cannabis Products and Permit Changes
The rescheduling FDA approved cannabis products implications are significant for clinical research and prescribing. This regulatory update moves certain cannabis-derived medications to Schedule III, easing permit requirements. Clinicians should…
Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
The DEA has placed several synthetic cannabinoids into Schedule I, highlighting their high abuse potential and lack of accepted medical use. This synthetic cannabinoids schedule I classification includes 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and…
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
The DEA synthetic cannabinoids Schedule I placement 2026 update includes cumyl-pegaclone, a synthetic cannabinoid now classified under Schedule I. This reflects regulatory efforts to control emerging psychoactive substances with high abuse potential.…
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA has enacted synthetic ketamine analog regulation by temporarily placing 2-fluorodeschloroketamine in Schedule I. This action highlights the challenges of controlling emerging designer drugs. Clinicians should monitor these regulatory changes…
DEA Updates Synthetic Dissociative Scheduling: Diphenidine in Schedule I
The DEA synthetic dissociative scheduling update places diphenidine in Schedule I due to its high abuse potential and lack of accepted medical use. This reflects regulatory efforts to control emerging novel psychoactive substances. Clinicians should…
The CB2 receptor, key in resistance to trastuzumab – Demócrata
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. CancerResearchSafetyPolicyPainAnxietyMental Health Why This Matters Clinicians treating HER2-positive breast cancer…